Publication: Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study<sup>*</sup>
Issued Date
2017-06-05
Resource Type
ISSN
10292403
10428194
10428194
Other identifier(s)
2-s2.0-85020251694
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Leukemia and Lymphoma. (2017), 1-8
Suggested Citation
Tadeusz Robak, Huiqiang Huang, Jie Jin, Jun Zhu, Ting Liu, Olga Samoilova, Halyna Pylypenko, Gregor Verhoef, Noppadol Siritanaratkul, Evgenii Osmanov, Juliana Pereira, Jiri Mayer, Xiaonan Hong, Rumiko Okamoto, Lixia Pei, Brendan Rooney, Helgi van de Velde, Franco Cavalli Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study<sup>*</sup>. Leukemia and Lymphoma. (2017), 1-8. doi:10.1080/10428194.2017.1321750 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/41858
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study<sup>*</sup>
Other Contributor(s)
Medical University of Lodz
Sun Yat-Sen University Cancer Center
Zhejiang University School of Medicine
Beijing Cancer Hospital
West China Hospital of Sichuan University
Lobachevsky State University of Nizhni Novgorod
null
KU Leuven– University Hospital Leuven
Mahidol University
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences
Universidade de Sao Paulo - USP
Fakultni Nemocnice Brno
Fudan University Shanghai Cancer Center
Tokyo Metropolitan Komagome Hospital
Janssen
Janssen Research and Development
Takeda Oncology
Ospedale San Giovanni
Sun Yat-Sen University Cancer Center
Zhejiang University School of Medicine
Beijing Cancer Hospital
West China Hospital of Sichuan University
Lobachevsky State University of Nizhni Novgorod
null
KU Leuven– University Hospital Leuven
Mahidol University
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences
Universidade de Sao Paulo - USP
Fakultni Nemocnice Brno
Fudan University Shanghai Cancer Center
Tokyo Metropolitan Komagome Hospital
Janssen
Janssen Research and Development
Takeda Oncology
Ospedale San Giovanni
Abstract
© 2017 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. The pivotal LYM-3002 study compared frontline rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) with bortezomib, rituximab, cyclophosphamide, doxorubicin and prednisone (VR-CAP) in newly diagnosed mantle cell lymphoma (MCL) patients for whom stem cell transplantation was not an option. This post hoc subanalysis of the VR-CAP data from LYM-3002 evaluated the effect of bortezomib dose intensity on OS in patients who completed ≥6 cycles of treatment. From the end of cycle 6, patients receiving ≥4.6 mg/m2/cycle of bortezomib had significantly longer OS (but not PFS) compared with those receiving <4.6 mg/m2/cycle by univariate analysis (HR 0.43 [95% CI: 0.23–0.80]; p = .0059). This association remained significant in multivariate analysis adjusting for baseline patient and disease characteristics (HR 0.40 [95% CI: 0.20–0.79]; p = .008]. Higher bortezomib dose intensity was the strongest predictor of OS in newly diagnosed MCL patients receiving VR-CAP. Clinicaltrials.gov identifier: NCT00722137.